New Enterprise Associates 16, L.P.'s Net Worth

$67.3 Million

Estimate Recalculated Sep 12, 2024 03:20PM EST

Who is New Enterprise Associates 16, L.P.?

New Enterprise Associates 16, L.P. has an estimated net worth of $67.3 Million. This is based on reported shares across multiple companies, which include Mirum Pharmaceuticals, Inc., GENOCEA BIOSCIENCES, INC., Metacrine, Inc., Trevi Therapeutics, Inc., Akouos, Inc., Black Diamond Therapeutics, Inc., Arsanis, Inc., Regulus Therapeutics Inc., Marker Therapeutics, Inc., and NeueHealth, Inc..

SEC CIK

New Enterprise Associates 16, L.P.'s CIK is 0001694560

Past Insider Trading and Trends

2020 was New Enterprise Associates 16, L.P.'s most active year for acquiring shares with 10 total transactions. New Enterprise Associates 16, L.P.'s most active month to acquire stocks was the month of May. 2020 was New Enterprise Associates 16, L.P.'s most active year for disposing of shares, totalling 7 transactions. New Enterprise Associates 16, L.P.'s most active month to dispose stocks was the month of May. 2019 saw New Enterprise Associates 16, L.P. paying a total of $46,749,499.56 for 23,917,283 shares, this is the most they've acquired in one year. In 2022 New Enterprise Associates 16, L.P. cashed out on 14,671,143 shares for a total of $750,662.12, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Mirum Pharmaceuticals, Inc. (MIRM) Snapshot price: $41.12

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-47.78%
-2.00M
—
—
2.19M
Jun 13
Form 4
∞
4.19M
$15.00
—
4.19M
Jul 22
Form 3
—
0
—
—
0
No matching records found

GENOCEA BIOSCIENCES, INC. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-10.38M
$0.07
-$750,662.12
0
May 24 - May 25
Form 4
+43.61%
3.15M
$2.25
$7,090,335.00
10.38M
Jul 24
Form 4
+65.40%
2.86M
$3.50
$9,999,997.00
7.23M
Jun 24
Form 4
+39.79%
9.95M
$0.47
$4,688,619.18
34.95M
Feb 14
Form 3
—
0
—
—
0
No matching records found

Metacrine, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-16.25%
-497.27K
$0.99
-$494,482.97
2.56M
Dec 10 - Dec 22
Form 4
∞
3.06M
$13.00
—
3.06M
Sep 18
Form 3
—
0
—
—
0
No matching records found

Trevi Therapeutics, Inc. (TRVI) Snapshot price: $2.95

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+33.78%
2.63M
$1.90
$4,999,998.20
10.42M
Apr 11
Form 4
+31.19%
1.85M
—
—
7.79M
Oct 18
Form 4
+33.78%
1.5M
$2.66
-$0.24
5.94M
Apr 3
Form 4
∞
4.44M
$10.00
—
4.44M
May 9
Form 3
—
0
—
—
0
No matching records found

Akouos, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-4.29M
—
—
0
Nov 30
Form 4
∞
4.29M
$17.00
—
4.29M
Jun 30
Form 3
—
0
—
—
0
No matching records found